Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665250 | 1.00 | CASP1 (0.54) | CASP1ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL7644966 | 0.84 | ALDH1A1 (0.49) | CASP1ALDH1A1MAPTSHBGCTBP2 | |
| SCHEMBL7642355 | 0.84 | ALDH1A1 (0.50) | CASP1ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL27953552 | 0.83 | AKR1B1 (0.50) | CASP1ALDH1A1MAPTGAAMEN1 | |
| SCHEMBL11209505 | 0.82 | CASP1 (0.49) | CASP1ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL25397941 | 0.81 | ALDH1A1 (0.48) | CASP1ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL513530 | 0.80 | PKM (0.53) | ALDH1A1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16672715 | 0.80 | L3MBTL1 (0.49) | CASP1ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL16672831 | 0.80 | KMT2A (0.51) | ALDH1A1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27166994 | 0.80 | NPC1 (0.42) | SHBGCTBP2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | claimed |
| CN-118215496-A | Immunomodulatory combinations of antigens and drug-lipid conjugates | 集成纳米治疗股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| WO-2023035068-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2023-03-16 | — | — | WO | claimed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-12459908-B2 | Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| US-20240252477-A1 | NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF | UNIVERSITA' DEGLI STUDI DI TORINO (60%) (IT) | 2024-08-01 | — | — | US | disclosed |
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | disclosed |
| CN-118215496-A | Immunomodulatory combinations of antigens and drug-lipid conjugates | 集成纳米治疗股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4334287-A1 | NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF | Università Degli Studi Di Torino (IT) | 2024-03-13 | — | — | EP | disclosed |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| WO-2006134485-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| EP-1732928-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1732893-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | Pfizer Japan, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
| WO-2005092895-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| US-4824868-A | 2-BENZYL-3-SUBSTITUTED-PHENOXYPROPYLAMINES, SEROTONIN UPTAKE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1989-04-25 | — | — | US | disclosed |
| US-4692469-A | 2-BENZYL-3-(SUBSTITUTED)-PHENOXYPROPYLAMINES; APPETITE SUPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
| US-4588746-A | Propylamine derivatives | CIBA-GEIGY CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | CASP1 1367/4885ALDH1A1 3621/4885MAPT 3120/4885 |
| US-12459908-B2 | Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties | PTGS1, PTGER1, PTGES2 | CASP1 83/4885ALDH1A1 24/4885MAPT 4043/4885 |
| US-20240252477-A1 | NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF | NLRP3, PYCARD, NLRP1 | CASP1 4/4885ALDH1A1 1873/4885MAPT 990/4885 |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | CASP1 1686/4885ALDH1A1 153/4885MAPT 3248/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | CASP1 349/4885ALDH1A1 2005/4885MAPT 685/4885 |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | PTGS1, PTGER1, PTGES2 | CASP1 83/4885ALDH1A1 24/4885MAPT 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.